Veracyte, Inc. · NASDAQ:VCYT
Veracyte — Technical Presentation (2020)
7 slides from Veracyte's technical presentation, 2020
Slide 1: Impact of Immune Assessment on Patterns of Care In Stage II Colon Cancer
Impact of Immune Assessment on Patterns of Care In Stage II Colon Cancer Afsaneh Barzi1, Graham M. Poage2, Aurelie Catteau3, Dewi Vernerey4 1. City of Hope Comprehensive Cancer Center, CA 2. HalioDx, Richmond, VA, 3. HalioDx, Marseille, FR 4. Methodology and Quality of Life in Oncology Unit, Besanço
Slide 2: Background
Background • Clinicopathologic risk assessment forms the basis of adjuvant treatment planning for the 25% of patients diagnosed with potentially curable stage II colon cancer (CC). Current risk factors are imperfect, resulting in misclassification and unnecessary postoperative interventions for many
Slide 3: Background
Background 4. Galon J et al. ASCO Symposium. 2020 5. Galon J et al. ASCO GI Symposium. 2019 • Immunoscore contributes the most prognostic information relative to other clinicopathological risk parameters in high-risk stage II colon cancer (Figure 1) even among the T4N0 subgroup (5) • Immunoscore ide
Slide 4: Methods
Methods Oncologists were presented with 10 patient profiles (real-life, de- identified stage II cases submitted for clinical Immunoscore testing) and queried for their recommendations (adjuvant chemotherapy and frequency of surveillance) via an online survey. Next, they took part in a 45min presenta
Slide 5: Results
Results • 55% of the physicians altered chemotherapy or surveillance practice patterns across the 10 patient cases, therefore the objective of the study was reached. • There was a higher rate of Chemotherapy Figure. 4 Impact of Immunoscore Testing on Clinical Decisions recommendation changes than mo
Slide 6: Results
Results Figure 5. Adjuvant Chemotherapy Decisions Based on Prognostic Factors (Pre-Immunoscore Testing) • In alignment with real-world clinical practice, cases with lymphovascular invasion, T4 stage, and poor differentiation status were most often recommended for adjuvant chemotherapy before testing
Slide 7: Conclusions
Conclusions • Immunoscore classification significantly impacted treatment decision-making for stage II colon cancer patients, especially those with high risk disease. • This impact can improve the value of care by reducing unnecessary adjuvant chemotherapy and improving the precision of care, by del